Low-grade Collecting Duct Carcinoma Of The Kidney: A Potential Mimic Of Conventional Clear Cell Carcinoma

10.5580/1464 ◽  
2001 ◽  
Vol 2 (1) ◽  
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Collecting Duct ◽  
Low Grade ◽  
Duct Carcinoma ◽  
Collecting Duct Carcinoma

scholarly journals Collision tumor of the kidney composed of clear cell carcinoma and collecting duct carcinoma treated with cabozantinib and nivolumab

2020 ◽  
Vol 2 ◽  
pp. 100039
Author(s):  
Carlos Eduardo Salazar-Mejía ◽  
Víctor Manuel Oyervides-Juárez ◽  
Blanca Otilia Wimer-Castillo ◽  
Oscar Vidal-Gutiérrez ◽  
Raquel Garza-Guajardo ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Collecting Duct ◽  
Collision Tumor ◽  
Duct Carcinoma ◽  
Collecting Duct Carcinoma

scholarly journals A very rare case report:Renal cell carcinoma metastasizing to the tonsil after 5 years of radical nephrectomy

2019 ◽  
Vol 6 (12) ◽  
pp. 4654-4656
Author(s):  
Yücel Kılıçkap ◽  
Mehmet Aktaş ◽  
Lezgin Kıran ◽  
Abdullah Gedik ◽  
M.Kamuran Bircan
Keyword(s):  
Cell Carcinoma ◽  
Rare Case ◽  
Clear Cell ◽  
Histopathological Examination ◽  
Collecting Duct ◽  
Neck Region ◽  
Duct Carcinoma ◽  
Head And Neck Region ◽  
Collecting Duct Carcinoma

Renal cell carcinoma (RCC), is the most common kidney cancer, that accounts for approximately  90% of all adult renal malignancies with 30% of patients presenting with metastasis at initial diagnosis.There are several reports of metastases developing after 10-20 years even if curative nephrectomy has been made. Clear cell (60%-75%), papillary (10%-15%), chromophobe (5%), and collecting duct carcinoma are well characterized subtypes of RCC.Renal cell carcinoma mainly metastasizes to the lungs,the bones,the liver,the lymph nodes and brain.Metastasis to the head and neck region is rare.In this case report we present a tonsil metastasis after 5 years of nephrectomy.Surgery with histopathological examination confirmed that metastasis of clear cell carcinom.The patient was successfully treated by surgery and referred to oncology.Later he was out of our follow-up.

scholarly journals Comprehensive Immunoprofiles of Renal Cell Carcinoma Subtypes

Cancers ◽  
2020 ◽  
Vol 12 (3) ◽  
pp. 602 ◽  
Author(s):  
Moonsik Kim ◽  
Jin Woo Joo ◽  
Seok Joo Lee ◽  
Yoon Ah Cho ◽  
Cheol Keun Park ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Collecting Duct ◽  
Cathepsin K ◽  
Renal Tumors ◽  
Duct Carcinoma ◽  
Epithelial Tumors ◽  
Papillary Type

In recent years, renal epithelial tumors have been among the fastest reclassifying tumors, requiring updates to the tumor classification system. Nonetheless, immunohistochemistry (IHC) remains the most widely used tool for renal epithelial tumors. In this proposal, we aimed to create the most efficient IHC panel for categorizing the diverse subtypes of renal tumors, and to find out more specific immunohistochemical results in each subtype or each antibody. A total of 214 renal tumors were analyzed using 10 possible IHC markers to differentiate subtypes, including three major renal cell carcinoma (RCC) subtypes, clear-cell type (50 cases), papillary type (50 cases), and chromophobe type (20 cases), and minor subtypes (MiT RCC, 13 cases; collecting duct carcinoma, 5 cases; and oncocytoma, 10 cases). A triple immunomarker (cytokeratin 7 (CK7)-carbonic anhydrase IX (CAIX)- alpha-methylacyl-CoA racemase (AMACR)) panel is useful in particular high-grade clear-cell tumors. If IHC remains ambiguous, the use of an adjunctive panel can be suggested, including CD10, epithelial membrane antigen, cathepsin K, c-kit, hepatocyte nuclear factor 1-β, and E-cadherin. For an efficient immunohistochemical strategy for subtyping of RCC, we conclude that the CK7-CAIX-AMACR panel is the best primary choice for screening subtyping.

Patterns of Care and Outcome of Clear Cell Carcinoma of the Head and Neck

2019 ◽  
Vol 161 (1) ◽  
pp. 98-104 ◽  
Author(s):  
Jamie Oliver ◽  
Peter Wu ◽  
Clifford Chang ◽  
Dylan Roden ◽  
Binhuan Wang ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Salivary Glands ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Tumor Grade ◽  
Low Grade ◽  
Major Salivary Gland ◽  
Positive Margins

Objective Clear cell carcinoma (CCC) is a rare salivary gland malignancy, believed to be generally low grade. We investigated CCC epidemiology and clinical behavior, using the National Cancer Database (NCDB). Study Design Retrospective cohort study. Setting NCDB. Subjects and Methods All CCCs of the salivary glands were selected between 2004 and 2015. Patient demographics, tumor characteristics, treatments, and survival were analyzed. Cox regression analyses were performed in treated patients. Results We identified 268 patients with CCC. Median age was 61 (21-90) years. Most were female (145, 54%). The most common site was oral cavity (119, 44%), followed by major salivary glands (68, 25%) and oropharynx (41, 15%). Most tumors were low grade (81, 68%) and stages I to II (117, 60.6%). Nodal (36, 17.5%) and distant metastases (6, 2.4%) were rare. Most were treated by surgery alone (134, 50.0%), followed by surgery and radiotherapy (69, 25.7%). Five-year overall survival (OS) was 77.6% (95% CI, 71.4%-84.2%). In univariate analysis, older age, major salivary gland and sinonasal site, stages III to IV, high grade, and positive margins were associated with worse OS. In multivariate analysis, only high tumor grade (hazard ratio [HR], 5.76; 95% CI, 1.39-23.85; P = .02), positive margins (HR, 4.01; 95% CI, 1.20-13.43; P = .02), and age ≥60 years (HR, 3.45; 95% CI, 1.39-8.55; P = .01) were significantly associated with OS. Conclusion We report the largest series of clear cell carcinomas of the head and neck. Outcomes are generally favorable following surgical-based treatments. In this series, pathologic tumor grade is associated with worse survival. Routine evaluation and reporting of tumor grade might better guide physicians in recommending appropriate treatments in this rare malignancy.

Expression of Aldo-keto-reductase 1B1 (AKR1B1) in tubulocytic carcinoma of kidney.

2016 ◽  
Vol 34 (2_suppl) ◽  
pp. 507-507
Author(s):  
Yasuhiro Hashimoto ◽  
Toshikazu Tanaka ◽  
Atsushi Imai ◽  
Shingo Hatakeyama ◽  
Takahiro Yoneyama ◽  
...  
Keyword(s):  
Who Classification ◽  
Collecting Duct ◽  
Renal Medulla ◽  
Papillary Renal Cell Carcinoma ◽  
Low Grade ◽  
Normal Kidney ◽  
High Concentration ◽  
Duct Carcinoma ◽  
Collecting Duct Carcinoma ◽  
Tubulocystic Carcinoma

507 Background: Tubulocystic carcinoma of the kidney (TubCC) is a new entity of tumor not listed in the 2004 WHO classification. The tumor comprised tubules forming duct-like structures exhibiting hobnail change, and resembled collecting duct carcinoma (CDC) by immunostaining; thus, this tumor was named low grade CDC. Since then, similar tumors have been reportedly called tubulocystic carcinoma (TubCC)We explored the possibility whether Aldo-keto-reductase-1B1 (AKR1B1), osmoregulatory protein and abundant in collecting duct, can be used as a marker for the pathologic diagnosis of TubCC. Methods: We prepared anti-AKR1B1 monoclonal antibodies, examined expression of AKR1B1 protein in the human normal kidney. Immunohistochemical expressions of AKR1B1 was examined on normal kidney, 4 cases of TubCC, 10 cases of papillary renal cell carcinoma (pRCC), and 10 cases of invasive urothelial carcinoma (iUC). Results: AKR1B1 expression distributed preferentially in the renal medulla and not in the cortex, reflected by its high concentration in medulla (2.12 ±1.35 μg/mg) compared with cortex (0.13 ± 0.03 μg/mg). Immunohistochemically, AKR1B1 was strongly positive in 3 of 4 TubCC cases. AKR1B1 was negative in cases of either iUC or pRCC. Conclusions: Although the present study was small and preliminary, AKR1B1 may be a more specific and potentially useful marker for TubCC. [Table: see text]

scholarly journals Aggressive co-existence: Collecting duct and clear cell carcinoma in the same kidney

2019 ◽  
Vol 45 (-1) ◽  
pp. 131-134
Author(s):  
Abdullah Hizir Yavuzhan ◽  
◽  
Mithat Eksi ◽  
Firat Baytekin ◽  
Volkan Tugcu ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Collecting Duct
Sign in / Sign up

Export Citation Format

Share Document